Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Petit and Petit 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (Itp)

James B. Bussel,John D. Grainger,Purificacion Garcia de Miguel,Jenny M. Despotovic,Franco Locatelli,Thirachit Chotsampancharoen, Elena K. Donyush,Julian Sevilla Navarro,Bunchoo Pongtanakul,Patcharee Komvilaisak,Darintr Sosothikul,Victor S. Blanchette, Guillermo I. Drelichman,Lakshmanan Krishnamurti,Nongnuch Sirachainan,Philip Connor,Michele David,Susanne Holzhauer,Vladimir Lebedev,Richard S. Lemons,Dagmar Pospisilova,Ugo Ramenghi,Koh B. Boayue,Dana C. Matthews,Lisa M. Marcello,Malini Iyengar,Geoffrey W. Chan,Karen D. Chagin,Dickens Theodore,Kalpana K. Bakshi,Christine K. Bailey

Blood（2014）

Cited 3|Views21
No score
Abstract
Background: Eltrombopag (EPAG), an oral thrombopoietin receptor agonist, is approved for treating thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) with insufficient response to prior therapy. Pooled data from 2 similarly designed, randomized, double-blind, placebo (PBO)-controlled studies investigating safety and efficacy of EPAG in pediatric ITP are presented here.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined